Hopefully you got out of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) early, as today the stock is trading 15.49% or 4.89 points down from last closing price of $31.57, reaching $26.68 at last check. The APLS share price has dropped in 3 of the last 5 days and is up 47.94% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 486,046 shares, and in total 804146 shares valued at $21.455 million were seen changing hands compared with 318100 shares valued at $10.042 million recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the APLS stock.
Apellis Pharmaceuticals, Inc. (APLS) shares have notched a 3-month gain of about 47.94%, but has still advanced 139.35% year to date. By comparison, the stock added 78.46% over the past 12 months, while it jumped 17.67% over the 1 month. The company’s market cap is around $1.88B, with its short interest ratio standing at 7%.
In the current trading session for APLS, the stock witnessed two major price actions, it rose to a high of $28.27 and was down as much as $26.5 at one point. The high recorded is very low when compared to their 52-week high which is $11.45. The 52-week high is now at -15.61 distance from current price. Their recent low of $33.18 represents a 144.54% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for APLS is $44.43, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The company recorded an interesting insider purchase transaction by the CFO on Aug 29, 2019. A Securities and Exchanges Commission filings show that Timothy Eugene Sullivan bought a total of 11,699 APLS shares that day for a sum of around $347,577. The filings show that the insider stake has now grown to 11,699 shares, currently worth $312,129. Apellis Pharmaceuticals, Inc. (APLS) insiders have acquired 11,699 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 10,000 shares. In total, individual insiders traded 21,699 shares in the business, which makes up 3.1% of 699,974 shares that were traded over a year. In the past 12 months, insiders have purchased 674,198 shares while the seller parted with 25,776 shares.
APLS‘s last price was up 37.62% as compared to the average trading price of 50 days recorded at $19.39 while enlarging the period to 200 trading days, the average closing price was $26.75. At present, there are 59.64 million in the total number of common shares owned by the public and among those 42.99 million shares have been available to trade. The percentage of shares being held by the company management was 1.7% while institutions stake was 66.2%. The company has generated negative returns on equity over the last 12 months (-104.8%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the APLS stock, there is another set of technicals that should be looked into and considered. Its -4.51% decline from moving average of $27.94 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Apellis Pharmaceuticals, Inc. — 7 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $45.1429 on shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), which corresponds to 69.77% upside potential than its current market price of $26.68 and implies potential despite the recent drop in the price. However, their current target price has fallen from $45.1429 a month ago and is up handily from the consensus target of $41.8333 a quarter ago.